Showing results (1021-1030 of 1,628) with videos related to

Sort By:
Pageof 163
The International Journal of Biological Markers|October 3, 2006
Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening seriesT Rubeca, S Rapi, M Confortini, et al.
The International Journal of Biological Markers|July 17, 2008
Gastrointestinal stromal tumors (GISTs): from science to targeted therapyR Sarmiento, P Bonginelli, F Cacciamani, et al.
The International Journal of Biological Markers|July 17, 2008
Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumorsM Seefeld, S El Tarhouny, A X C Fan, et al.
The International Journal of Biological Markers|June 6, 2007
Levels of circulating cell-free serum DNA in benign and malignant breast lesionsR A Zanetti-Dällenbach, S Schmid, E Wight, et al.
The International Journal of Biological Markers|May 24, 2007
Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challengesF Cappuzzo, L Toschi, G Finocchiaro, et al.
The International Journal of Biological Markers|May 24, 2007
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapyG Tortora, T Gelardi, F Ciardiello, et al.
The International Journal of Biological Markers|May 24, 2007
Clinical management of cutaneous toxicity of anti-EGFR agentsM Monti, S Motta
The International Journal of Biological Markers|January 1, 1991
Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer managementJ L Jensen, G D Maclean, M R Suresh, et al.
The International Journal of Biological Markers|July 14, 2005
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaborationR Riisbro, I J Christensen, H J Nielsen, et al.
The International Journal of Biological Markers|July 14, 2005
Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapyJ Morote, S Esquena, J M Abascal, et al.
Pageof 163